GoAI
Get started
Hyperfine, Inc. logo

Hyperfine, Inc.

HYPR

NASDAQHealthcareMedical - Devices

Open in GoAI

Previous close

$0.9021

−$0.002 · -0.22%

Aug 21, 4:00 PM ET

HYPR company overview

Regular session · ET · Market data may be delayed.

GoAI snapshot

AI-powered factor overview

Jul 10, 2026

GoAI score

Sell

Trim exposure — unfavorable risk-reward

Valuation

62

Undervalued

Momentum

29

Weakening

Sentiment

32

Bearish

Risk resilience

28

High Risk

Full GoAI research

Thesis, catalysts, evidence, and risk analysis.

View full GoAI research

AI-generated, informational only, and not investment advice.

Company profile

Company website

Hyperfine, Inc., a health technology company, engages in the production, supply, service, and commercialization of magnetic resonance imaging (MRI) products. Its Swoop Portable MR Imaging System produces images at a lower magnetic field strength than conventional MRI scanners. The company also offers support and technical assistance services, as well as Hyperfine Image Viewer, a cloud picture archiving and communication system. It serves intensive care units, neurology offices, emergency departments, and comprehensive and primary stroke accredited facilities through direct sales and distributors in the United States, Canada, the United Kingdom, other European and Middle Eastern markets, Australia, and New Zealand. The company was founded in 2014 and is based in Guilford, Connecticut.

Industry
Medical - Devices
Sector
Healthcare
Headquarters
US
CEO
Maria Degois Sainz
Listed since
Jan 28, 2021
Employees
102

Market position

Day range

Current $0.9021

52-week range

Current $0.9021

Open
$0.9118
Previous close
$0.9041
Volume
532.21K
0.58× average
Average volume
914.6K
Average daily volume
Market cap
75.97M USD
Beta
1.43
Market reference 1
50-day average
$1.1179
-19.30% below average
200-day average
$1.1863
-23.95% below average

Financials

Financial snapshot

Latest / TTM

Valuation & yield

Enterprise value
57.48M USD
P/E (TTM)
-2.36×
P/B (TTM)
2.45×
P/S (TTM)
4.59×
EV / EBITDA
-1.72×
Earnings yield
-38.56%
Free cash flow yield
-31.58%
Dividend yield
0.00%

Profitability & efficiency

Gross margin
51.41%
Operating margin
-203.27%
Net margin
-210.75%
Return on equity
-86.76%
Return on assets
-64.37%
Return on invested capital
-84.71%

Financial health

Debt / equity
0.36×
Current ratio
4.34×

Financial statements

Margin trends

Profitability as a percentage of reported revenue.

Gross marginOperating marginNet margin
Gross, operating, and net margin trends488%-1266%-3020%-4775%Gross margin, FY2021: -78.01%Gross margin, FY2022: 13.31%Gross margin, FY2023: 43.12%Gross margin, FY2024: 45.70%Gross margin, FY2025: 49.79%Operating margin, FY2021: -4336.10%Operating margin, FY2022: -1084.15%Operating margin, FY2023: -436.14%Operating margin, FY2024: -335.33%Operating margin, FY2025: -273.43%Net margin, FY2021: -4333.76%Net margin, FY2022: -1073.73%Net margin, FY2023: -401.00%Net margin, FY2024: -315.90%Net margin, FY2025: -262.29%FY2021FY2022FY2023FY2024FY2025
Gross margin FY2021 -78.01%. Gross margin FY2022 13.31%. Gross margin FY2023 43.12%. Gross margin FY2024 45.70%. Gross margin FY2025 49.79%. Operating margin FY2021 -4336.10%. Operating margin FY2022 -1084.15%. Operating margin FY2023 -436.14%. Operating margin FY2024 -335.33%. Operating margin FY2025 -273.43%. Net margin FY2021 -4333.76%. Net margin FY2022 -1073.73%. Net margin FY2023 -401.00%. Net margin FY2024 -315.90%. Net margin FY2025 -262.29%.

Income trends

Revenue

13.56M USD+5.22%

Operating income

−37.09M USD+14.20%

Net income

−35.57M USD+12.64%
Income trends across reported periods22.31M USD−12.67M USD−47.64M USD−82.62M USDRevenue, FY2021: 1.5M USDRevenue, FY2022: 6.81M USDRevenue, FY2023: 11.03M USDRevenue, FY2024: 12.89M USDRevenue, FY2025: 13.56M USDOperating income, FY2021: −64.87M USDOperating income, FY2022: −73.87M USDOperating income, FY2023: −48.12M USDOperating income, FY2024: −43.22M USDOperating income, FY2025: −37.09M USDNet income, FY2021: −64.83M USDNet income, FY2022: −73.16M USDNet income, FY2023: −44.24M USDNet income, FY2024: −40.72M USDNet income, FY2025: −35.57M USDFY2021FY2022FY2023FY2024FY2025
Revenue FY2021 1.5M USD. Revenue FY2022 6.81M USD. Revenue FY2023 11.03M USD. Revenue FY2024 12.89M USD. Revenue FY2025 13.56M USD. Operating income FY2021 −64.87M USD. Operating income FY2022 −73.87M USD. Operating income FY2023 −48.12M USD. Operating income FY2024 −43.22M USD. Operating income FY2025 −37.09M USD. Net income FY2021 −64.83M USD. Net income FY2022 −73.16M USD. Net income FY2023 −44.24M USD. Net income FY2024 −40.72M USD. Net income FY2025 −35.57M USD.
Metric (USD)FY2025FY2024FY2023FY2022FY2021
Revenue13.56M USD12.89M USD11.03M USD6.81M USD1.5M USD
Cost of goods sold6.81M USD7M USD6.28M USD5.91M USD2.66M USD
Gross profit6.75M USD5.89M USD4.76M USD907K USD−1.17M USD
Research and development17.45M USD22.5M USD22.49M USD28.16M USD25.84M USD
Selling, general, and administrative26.39M USD26.62M USD30.38M USD46.63M USD37.86M USD
Operating expenses43.84M USD49.12M USD52.87M USD74.78M USD63.7M USD
Interest income1.02M USD2.49M USD3.84M USD761K USD18K USD
Depreciation and amortization2.2M USD1.01M USD1.05M USD1.02M USD726K USD
Operating income−37.09M USD−43.22M USD−48.12M USD−73.87M USD−64.87M USD
Net income−35.57M USD−40.72M USD−44.24M USD−73.16M USD−64.83M USD

Company facts updated Aug 24, 2026.

Earnings

EPS beat rate
18%
2 beats, 1 miss, 8 met estimates
Average EPS surprise
+1.30%
11 comparable reports
Latest EPS result
-0.09
Estimate -0.09 · Met by 0.00%

EPS: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly EPS actual values compared with estimates-0.07-0.11-0.16-0.2Q1 '25BeatQ2 '25MetQ3 '25MetQ4 '25MissQ1 '26MetQ2 '26MetQ3 '26MetQ4 '26Estimate
Q1 2025, reported Mar 17, 2025: actual -0.14, estimate -0.16, surprise +12.50%, Beat. Q2 2025, reported May 13, 2025: actual -0.12, estimate -0.12, surprise 0.00%, Met estimate. Q3 2025, reported Aug 13, 2025: actual -0.12, estimate -0.12, surprise 0.00%, Met estimate. Q4 2025, reported Nov 13, 2025: actual -0.11, estimate -0.1, surprise -10.00%, Miss. Q1 2026, reported Mar 18, 2026: actual -0.08, estimate -0.08, surprise 0.00%, Met estimate. Q2 2026, reported May 12, 2026: actual -0.09, estimate -0.09, surprise 0.00%, Met estimate. Q3 2026, reported Aug 6, 2026: actual -0.09, estimate -0.09, surprise 0.00%, Met estimate. Q4 2026, reported Nov 12, 2026: actual —, estimate -0.08, surprise —, Comparison unavailable.

Revenue: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly Revenue actual values compared with estimates5.55M4.33M3.11M1.88MQ1 '25BeatQ2 '25MissQ3 '25MissQ4 '25MissQ1 '26BeatQ2 '26BeatQ3 '26MissQ4 '26Estimate
Q1 2025, reported Mar 17, 2025: actual 2.32M USD, estimate 2.3M USD, surprise +0.91%, Beat. Q2 2025, reported May 13, 2025: actual 2.14M USD, estimate 3.19M USD, surprise -33.06%, Miss. Q3 2025, reported Aug 13, 2025: actual 2.7M USD, estimate 3M USD, surprise -10.13%, Miss. Q4 2025, reported Nov 13, 2025: actual 3.44M USD, estimate 5.3M USD, surprise -35.15%, Miss. Q1 2026, reported Mar 18, 2026: actual 5.29M USD, estimate 5.16M USD, surprise +2.68%, Beat. Q2 2026, reported May 12, 2026: actual 3.9M USD, estimate 3.54M USD, surprise +10.25%, Beat. Q3 2026, reported Aug 6, 2026: actual 3.9M USD, estimate 4.13M USD, surprise -5.58%, Miss. Q4 2026, reported Nov 12, 2026: actual —, estimate 5.13M USD, surprise —, Comparison unavailable.

Analyst ratings

Third-party consensus; not a GoAI recommendation.

Analyst price target

Average target

$2.00

121.70% upside
Past 12 months12-month forecastHigh $2.00Average $2.00Low $2.00

Rating distribution

4 ratings

Limited analyst sample: 4 ratings. Interpret the distribution with caution.

Strong buy00%
Buy375%
Hold125%
Sell00%
Strong sell00%

HYPR peers

Amgen Inc. logo

AMGN

Amgen Inc.

$439.33

+1.29%

Gilead Sciences, Inc. logo

GILD

Gilead Sciences, Inc.

$146.12

+1.87%

Vertex Pharmaceuticals Incorporated logo

VRTX

Vertex Pharmaceuticals Incorporated

$548.05

+1.44%

Intuitive Surgical, Inc. logo

ISRG

Intuitive Surgical, Inc.

$378.81

+1.16%

Sanofi logo

SNY

Sanofi

$45.85

+1.55%

Regeneron Pharmaceuticals, Inc. logo

REGN

Regeneron Pharmaceuticals, Inc.

$834.04

+0.90%

ETFs holding HYPR

Funds reporting this stock among their holdings, ordered by reported position size.

Vanguard Morningstar Total Stock Market ETF logoVanguard Morningstar Total Stock Market ETFVTI
Market value
2.19M
Weight
0.00%
AUM
2.3T USD
Expense ratio
0.03%
Price / 1D
$378.24+0.44%
iShares Russell 2000 ETF logoiShares Russell 2000 ETFIWM
Market value
1.5M
Weight
0.00%
AUM
81.62B USD
Expense ratio
0.19%
Price / 1D
$299.96+0.77%
Vanguard Extended Market ETF logoVanguard Extended Market ETFVXF
Market value
879.36K
Weight
0.00%
AUM
93.7B USD
Expense ratio
0.05%
Price / 1D
$245.53+0.82%
iShares Russell 2000 Growth ETF logoiShares Russell 2000 Growth ETFIWO
Market value
664.69K
Weight
0.00%
AUM
15.16B USD
Expense ratio
0.24%
Price / 1D
$387.37+1.24%
Vanguard Russell 2000 ETF logoVanguard Russell 2000 ETFVTWO
Market value
415.01K
Weight
0.00%
AUM
17.4B USD
Expense ratio
0.06%
Price / 1D
$121.25+0.74%
iShares Micro-Cap ETF logoiShares Micro-Cap ETFIWC
Market value
239.87K
Weight
0.02%
AUM
1.53B USD
Expense ratio
0.60%
Price / 1D
$198.39+1.10%
Vanguard Russell 2000 Growth ETF logoVanguard Russell 2000 Growth ETFVTWG
Market value
79.15K
Weight
0.00%
AUM
1.7B USD
Expense ratio
0.06%
Price / 1D
$282.73+1.21%
Global X - Russell 2000 ETF logoGlobal X - Russell 2000 ETFRSSL
Market value
33.54K
Weight
—
AUM
1.53B USD
Expense ratio
0.08%
Price / 1D
$117.49+0.86%

Continue in GoAI

Research HYPR

research.disclaimer